帶狀皰疹感染治療市場－全球產業規模、佔有率、趨勢、機會、預測：按治療類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球帶狀皰疹治療市場預計將從 2025 年的 2.7112 億美元成長到 2031 年的 3.4147 億美元，複合年成長率為 3.92%。

該市場涵蓋多種治療和預防方法，例如抗病毒藥物療法、用於治療神經性疼痛的鎮痛藥物以及旨在預防水痘-帶狀皰疹病毒感染的重組疫苗。推動這一市場成長的主要因素是全球免疫老化進程，這與人口老化密切相關。免疫老化自然會導致細胞免疫力下降，並增加病毒重新運作的易感性。此外，免疫功能低下人群中免疫力缺乏皰疹發病率的上升以及大力推廣成人疫苗接種計劃的公共衛生宣傳活動也是持續推動市場需求的潛在因素。然而，先進的重組疫苗和長期疼痛管理療法的高成本限制了成本敏感地區的患者獲得這些藥物的機會，市場面臨許多障礙。這些經濟障礙可能會阻礙最佳治療方案的廣泛應用和堅持，並抑制新興經濟體的收入成長。例如，預計到2025年，10%至18%的帶狀皰疹患者將發展為帶狀皰疹帶狀皰疹後遺症神經痛，併發症需要長期且往往費用高昂的醫療干預。推動該市場成長要素是全球人口的快速老化，這需要擴大預防措施並實施政府主導的免疫接種方案。隨著免疫老化削弱老年人對水痘-帶狀皰疹病毒的自然防禦能力，各國政府正擴大將帶狀皰疹疫苗納入公共衛生補貼計劃，以減輕併發症帶來的長期經濟負擔。這種結構性轉變在人口老化程度高的地區的關鍵政策更新中尤其明顯。在這些地區，補貼申請與市場擴張直接相關，例如日本決定從2025年起將帶狀皰疹疫苗納入其針對65歲及以上人群的國家免疫接種計劃。此類監管支持有效地將潛在需求轉化為製造商的可觀收入，從而增強了市場的永續性。此外，抗病毒藥物研發管線和新一代疫苗技術的持續進步，正透過滿足耐受性和給藥效率的未滿足需求，動態地改變著競爭格局。製藥公司正致力於開發改良的候選藥物，以降低局部副作用的嚴重程度，同時保持與現有標準療法相當的療效，從而提高患者的依從性。 Curevo Vaccine公司的佐劑合併亞次單位疫苗候選藥物在第二期臨床試驗中，於第二劑接種後一個月內實現了100%的疫苗反應率，這一成果印證了上述進展。此類臨床創新對於涵蓋絕大多數未接種疫苗的人至關重要，尤其考慮到2024年，美國的累積疫苗接種率預計僅為建議成人接種率的39%。

市場促進因素

全球人口老化是推動市場發展的主要人口因素，因此需要擴大預防措施和政府主導的免疫接種計畫。隨著免疫力老化導致老年人對水痘帶狀皰疹病毒的自然免疫力下降，各國政府正擴大將帶狀皰疹疫苗納入公共衛生補貼計劃，以減輕併發症帶來的長期經濟負擔。這項結構性轉變得益於人口老化程度高的地區的關鍵政策更新，而補貼申請則與市場規模擴張直接相關。根據日本製藥協會（Pharma Japan）報道，日本厚生勞動省於2024年12月核准了一項計劃，擬從2025會計年度開始將帶狀皰疹疫苗納入65歲及以上人群的國家免疫接種計劃。這項監管支持將把老齡人口中蘊藏的巨大潛在需求轉化為製藥公司可靠的收入來源，從而確保市場在經濟波動中永續性。抗病毒藥物研發管線和新一代疫苗技術的進步，正透過滿足耐受性和給藥效率方面尚未滿足的需求，不斷重塑競爭格局。製藥公司正優先研發改良型候選疫苗，以降低局部副作用的嚴重程度，同時維持與現有標準療法相當的療效，進而提高病患的遵從性。例如，Curevo Vaccine公司於2024年1月宣布，其佐劑合併次單位疫苗候選產品在第二期臨床試驗的直接對照試驗中，於接種第二劑後一個月達到了100%的疫苗反應率。這些臨床創新對於涵蓋絕大多數未接種疫苗的人至關重要，尤其是在美國成年人累積疫苗接種率僅為建議接種人群的39%的情況下（根據葛蘭素史克公司2024年報告）。

市場挑戰

高重組疫苗和長期疼痛管理療法的高成本是全球帶狀皰疹治療市場擴張的主要障礙。這一經濟壁壘顯著限制了市場滲透率，尤其是在醫療預算緊張的新興經濟體和成本敏感地區。隨著世界人口老化，對有效預防帶狀皰疹的臨床需求日益成長，但多劑疫苗接種方案所需的巨額投資往往成為患者和醫療機構的負擔。因此，由於高昂的價格迫使許多人放棄必要的預防保健和治療，製造商難以將大量高風險族群轉化為實際收入。這種可負擔治療方案取得方面的差異導致市場格局碎片化，成長主要局限於擁有完善健保體系的國家，巨大的潛在市場仍未開發。高成本與低疫苗接種率之間的直接關聯阻礙了該行業利用病毒感染率上升所帶來的商機。根據國際老齡聯盟（IFA）的數據，即使到了2025年，每劑疫苗約150美元的高昂自費成本仍然是一大障礙，導致在沒有公共資金支持的地區，疫苗接種率僅為32.9%。如此低的接種率表明，價格障礙正在直接阻礙市場成長，並限制永續的產生收入。

市場趨勢

全球帶狀皰疹治療市場兩大最顯著的趨勢是：探索新一代佐劑系統以及重組次單位疫苗的普及應用。新一代佐劑系統的探索旨在提高疫苗耐受性，從而改變預防醫學市場的格局，有效解決目前標準治療疫苗的高反應性問題。產業公司正優先研發專有佐劑配方，例如 CpG 1018，旨在顯著降低局部和全身不利事件，同時維持高免疫抗原性。最佳化安全性對於克服疫苗猶豫和提高老年族群的疫苗接種率至關重要。根據 Dynavax Technologies Corporation 在 2025 年 8 月發布的新聞稿中透露，其候選疫苗 Z-1018 在接種第二劑後一個月內實現了 100% 的體液免疫應答率，同時注射部位反應發生率更低，耐受性也優於現有標準疫苗。隨著新參與企業推進其候選疫苗達到監管里程碑，重組次單位疫苗的主導地位正在加速提升，這不僅挑戰了現有的重組疫苗壟斷地位，也對活病毒疫苗的市場佔有率造成了實質性的削弱。這一趨勢的特徵是次單位疫苗在全球市場的擴張，其驅動力在於需要強大的供應鏈和多元化的採購管道來滿足免疫規劃的需求。近期監管方面的進展也為此轉變提供了強力支撐。據江蘇瑞克生物科技有限公司稱，2025年12月，REC610新藥認證申請（NDA）的公告顯示，該候選疫苗的申請已獲得藥品審查中心的正式受理，這確立了其在不斷擴大的重組亞次單元市場中的重要挑戰者地位。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：帶狀皰疹感染治療的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（處方療法、輔助療法）
  • 給藥途徑（口服、靜脈注射、其他）
  • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美帶狀皰疹治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲帶狀皰疹治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區帶狀皰疹治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲帶狀皰疹治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲帶狀皰疹治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球帶狀皰疹感染治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• GSK plc.
• Bausch Health Companies Inc.
• Renata Limited
• Novan, Inc.
• Teva Pharmaceuticals USA, Inc.
• Pfizer Inc.
• Apotex Inc.
• Sandoz Canada Inc.
• Novartis Pharmaceuticals Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Herpes Zoster Infection Treatment Market is projected to expand from USD 271.12 Million in 2025 to USD 341.47 Million by 2031, achieving a Compound Annual Growth Rate of 3.92%. This market encompasses various therapeutic and preventative approaches, including antiviral pharmacotherapies, analgesic agents for managing neuropathic pain, and recombinant vaccines aimed at preventing the varicella-zoster virus. Key drivers fueling this growth include the escalating rate of global immunosenescence within the aging population, which naturally diminishes cell-mediated immunity and heightens susceptibility to viral reactivation. Additionally, the increasing incidence of shingles among immunocompromised individuals and strong public health campaigns advocating for adult immunization schedules are fundamental catalysts for sustained market demand. Nevertheless, the market faces a significant hurdle due to the high cost associated with advanced recombinant vaccines and long-term pain management therapies, which limits accessibility in cost-sensitive regions. This economic barrier hinders widespread adoption and adherence to optimal treatment protocols, potentially impeding revenue growth in emerging economies. For instance, in 2025, an estimated 10% to 18% of individuals diagnosed with herpes zoster developed postherpetic neuralgia, a complication demanding prolonged and often expensive medical intervention. The primary demographic engine for the market is the rapidly aging global population, which necessitates expanded prophylactic measures and state-sponsored immunization protocols. As immunosenescence weakens the natural defense against the varicella-zoster virus in older adults, governments are increasingly integrating shingles vaccinations into public health subsidies to mitigate the long-term economic burden of complications. This structural shift is exemplified by major policy updates in regions with high geriatric densities, where subsidized access directly correlates with market volume expansion, as seen in Japan's decision to include shingles vaccines in its national immunization program for individuals aged 65 and older from FY2025. This regulatory support effectively translates high latent demand into active revenue streams for manufacturers, bolstering market sustainability. Furthermore, continuous advancements in antiviral therapeutic pipelines and next-generation vaccine technologies are dynamically reshaping the competitive landscape by addressing unmet needs regarding tolerability and administration efficiency. Pharmaceutical developers are focusing on formulating improved candidates that offer comparable efficacy to existing standards while reducing the severity of local adverse events, thereby enhancing patient compliance. This progress is underscored by developments such as Curevo Vaccine's adjuvanted subunit vaccine candidate achieving a 100% vaccine response rate one month after the second dose in a Phase 2 trial. These clinical innovations are crucial for capturing the substantial portion of the unvaccinated population, especially considering that as of 2024, the cumulative immunization penetration rate in the US had only reached 39% of the recommended adult population.

Market Driver

The rapidly aging global population serves as the primary demographic engine for the market, necessitating expanded prophylactic measures and state-sponsored immunization protocols. As immunosenescence weakens the natural defense against the varicella-zoster virus in older adults, governments are increasingly integrating shingles vaccinations into public health subsidies to mitigate the long-term economic burden of complications. This structural shift is evidenced by major policy updates in regions with high geriatric densities, where subsidized access directly correlates with market volume expansion. According to Pharma Japan, in December 2024, the Japanese health ministry approved a plan to include shingles vaccines in the national immunization program for individuals aged 65 and older from FY2025. This regulatory support effectively converts the high latent demand within the aging demographic into active revenue streams for manufacturers, ensuring market sustainability despite economic fluctuations. Advancements in antiviral therapeutic pipelines and next-generation vaccine technologies are continually reshaping the competitive landscape by addressing unmet needs regarding tolerability and administration efficiency. Pharmaceutical developers are prioritizing the formulation of improved candidates that offer comparable efficacy to existing standards while reducing the severity of local adverse events, thereby improving patient compliance. Demonstrating this progress, according to Curevo Vaccine, in January 2024, their adjuvanted subunit vaccine candidate achieved a 100% vaccine response rate one month after the second dose in a head-to-head comparison in a Phase 2 trial. These clinical innovations are critical for capturing the significant portion of the unvaccinated population, particularly as GSK reported in 2024 that the cumulative immunization penetration rate in the US had only reached 39% of the recommended adult population.

Market Challenge

The high cost structure associated with advanced recombinant vaccines and long-term pain management therapies constitutes a formidable barrier to the expansion of the Global Herpes Zoster Infection Treatment Market. This economic impediment severely restricts market penetration, particularly in emerging economies and cost-sensitive regions where healthcare budgets are tightly constrained. Although the clinical necessity for effective shingles prevention is rising due to global aging, the substantial financial investment required for multi-dose vaccine regimens often deters both individual patients and institutional payers. Consequently, manufacturers encounter significant difficulties in converting the high volume of at-risk individuals into actual revenue, as the prohibitive pricing compels many to forego necessary preventative care or treatment. This affordability gap creates a fragmented market landscape where growth is largely confined to nations with robust reimbursement frameworks, leaving vast potential markets untapped. The direct correlation between high costs and low uptake stifles the industry's ability to capitalize on the increasing prevalence of the virus. According to the International Federation on Ageing, in 2025, the significant out-of-pocket expense of approximately $150 per dose remained a primary barrier, resulting in vaccination coverage rates of just 32.9% in jurisdictions lacking public funding. Such low adherence figures demonstrate how pricing barriers directly hamper the market's trajectory and limit sustained revenue generation.

Market Trends

The two most significant trends in the Global Herpes Zoster Infection Treatment Market are the research into next-generation adjuvant systems and the transition toward recombinant subunit vaccine dominance. Research into Next-Generation Adjuvant Systems for Improved Tolerability is reshaping the prophylactic landscape by addressing the high reactogenicity associated with current standard-of-care vaccines. Industry players are prioritizing the development of proprietary adjuvant formulations, such as CpG 1018, which aim to maintain high immunogenicity while significantly reducing local and systemic adverse events. This focus on optimizing the safety profile is critical for overcoming vaccine hesitancy and improving uptake rates in the elderly population. According to Dynavax Technologies Corporation, in August 2025, in a press release regarding Phase 1/2 trial results, their Z-1018 candidate demonstrated a 100% humoral vaccine response rate one month after the second dose while exhibiting a favorable tolerability profile with lower rates of injection site reactions compared to the existing standard. The Transition Toward Recombinant Subunit Vaccine Dominance is accelerating as new market entrants advance their candidates through regulatory milestones, challenging the monopoly of existing recombinant options and marking the definitive decline of live-attenuated vaccines. This trend is characterized by the expansion of the subunit class into global markets, driven by the need for robust supply chains and diversified sourcing to meet the demands of immunization programs. This shift is substantiated by recent regulatory progress; according to Jiangsu Recbio Technology Co., Ltd., in December 2025, in an announcement regarding the New Drug Application (NDA) for REC610, the candidate's application was officially accepted by the Center for Drug Evaluation, positioning it as a key challenger in the expanding recombinant subunit market.

Key Market Players

• GSK plc.
• Bausch Health Companies Inc.
• Renata Limited
• Novan, Inc.
• Teva Pharmaceuticals USA, Inc.
• Pfizer Inc.
• Apotex Inc.
• Sandoz Canada Inc.
• Novartis Pharmaceuticals Corporation

Report Scope

In this report, the Global Herpes Zoster Infection Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herpes Zoster Infection Treatment Market, By Treatment Type

• Prescription Treatment
• Supporting Treatment

Herpes Zoster Infection Treatment Market, By Route of administration

• Oral
• Intravenous
• Others

Herpes Zoster Infection Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Herpes Zoster Infection Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herpes Zoster Infection Treatment Market.

Available Customizations:

Global Herpes Zoster Infection Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Herpes Zoster Infection Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Prescription Treatment, Supporting Treatment)
  • 5.2.2. By Route of administration (Oral, Intravenous, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Herpes Zoster Infection Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Route of administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Herpes Zoster Infection Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Route of administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Herpes Zoster Infection Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Route of administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Herpes Zoster Infection Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Route of administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Herpes Zoster Infection Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Route of administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Herpes Zoster Infection Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Route of administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Herpes Zoster Infection Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Route of administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Herpes Zoster Infection Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Route of administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Herpes Zoster Infection Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Route of administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Herpes Zoster Infection Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Route of administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Herpes Zoster Infection Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Herpes Zoster Infection Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Herpes Zoster Infection Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Herpes Zoster Infection Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Herpes Zoster Infection Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Route of administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Herpes Zoster Infection Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Route of administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Herpes Zoster Infection Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Herpes Zoster Infection Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Herpes Zoster Infection Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Herpes Zoster Infection Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Herpes Zoster Infection Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Herpes Zoster Infection Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Herpes Zoster Infection Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Herpes Zoster Infection Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Herpes Zoster Infection Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GSK plc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bausch Health Companies Inc.
• 15.3. Renata Limited
• 15.4. Novan, Inc.
• 15.5. Teva Pharmaceuticals USA, Inc.
• 15.6. Pfizer Inc.
• 15.7. Apotex Inc.
• 15.8. Sandoz Canada Inc.
• 15.9. Novartis Pharmaceuticals Corporation

16. Strategic Recommendations

17. About Us & Disclaimer